Combining Rituxan with Mavenclad or Zelboraf upfront can extend remissions safely and should become standard first-line therapy for hairy cell leukemia.
Dr. Farhad Ravandi-Kashani
Advertisement
Ravandi is the Dallas/Fort Worth Living Legend Chair for Cancer Research III, professor of medicine and chief of section of acute myeloid leukemia in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
Articles by Dr. Farhad Ravandi-Kashani
Advertisement
Latest Updated Articles
Advertisement
Advertisement
